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The antigens in the P1PK blood group system are carried on 
glycosphingolipids. The system currently includes three different 
antigens, P1, Pk, and NOR. The P1 antigen was disovered in 1927 
by Landsteiner and Levine, and Pk and NOR were described in 
1951 and 1982, respectively. As in the ABO system, naturally 
occurring antibodies of the immunoglobulin (Ig) M or IgG class, 
against the missing carbohydrate structures, can be present in 
the sera of people lacking the corresponding antigen. Anti-P1 is 
generally a weak and cold-reactive antibody not implicated in 
hemolytic transfusion reaction (HTR) or hemolytic disease of 
the fetus and newborn while Pk antibodies can cause HTR, and 
anti-NOR is regarded as a polyagglutinin. A higher frequency of 
miscarriage is seen in women with the rare phenotypes p, P1k, 
and P2k. Furthermore, the Pk and P1 antigens have wide tissue 
distributions and can act as host receptors for various pathogens 
and toxins. Why p individuals lack not only Pk and P expression 
but also P1 has been a longstanding enigma. Recently, it was 
shown that the same A4GALT-encoded galactosyltransferase 
synthesizes both the P1 and Pk antigens and that a polymorphism 
in a new exon in this gene predicts the P1 and P2 phenotypes. 
Immunohematology 2013;29:25–33.
Historical Aspects
In 1927, Landsteiner and Levine1 found antibodies to an 
antigen they called P (now known as the P1 antigen). In 1951, 
the Jay blood group “system” was discovered, containing one 
antigen, Tja, and its corresponding antibody, anti-Tja.2 Four 
years later, Sanger3 found a relationship between the P (P1) 
and the Jay systems. The P (P1) antigen was absent from all 
red blood cells (RBCs) with the rare Tj(a–) phenotype. The 
antigen P was then renamed to P1 and the Tj(a–) phenotype 
became the p (or PP1Pknull) phenotype.3 Anti-P was originally 
recognized in 1955 as a component of anti-Tja (now designated 
anti-PP1Pk), the mix of naturally occurring antibodies in sera 
of people with the p phenotype.3 The first individual lacking 
the P antigen was described in 1959 by Matson et al.,4 and in 
the same paper the Pk antigen and anti-Pk were first mentioned. 
The authors also noted the association with the P blood group 
system.4  
Nevertheless, the relationship between the different 
antigens was not fully understood at that time. In the fifth 
edition of Blood Groups in Man,5 the authors declare “we began 
to feel lost in amazement at the complexity of the P system.” 
Indeed, this feeling has lingered (and still does) among many 
of us who work with these questions. However, the first paper 
explaining the relationship between the P1, Pk, and P antigens, 
as well as determining the biochemical structure of these 
glycolipids, was published in 1974 by Naiki et al.6 See Figure 
1 for a schematic representation of the antigens discussed in 
this review. 
Nomenclature
The history of nomenclature for the P1 and Pk antigens 
is complicated and sometimes confusing. The P1 antigen, 
originally called P, used to belong to the P blood group system 
and the Pk antigen to the GLOB collection (ISBT no. 209). 
However, the P antigen (globoside, Gb4) did not belong to the 
original P system, but has now been made the only antigen in 
the GLOB blood group system (ISBT no. 028).7,8 Now that it 
is clear that the A4GALT gene is responsible for both the P1 
and Pk antigens (see later section), the Pk antigen has joined 
the P1 antigen and the system name has been changed to the 
P1PK blood group system (ISBT no. 003) to reflect the two 
























Fig. 1 The antigens in the P1PK blood group system, together with 
the related P antigen.
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major antigens in it (Table 1).9 The NOR antigen was assigned 
to the P1PK system by the ISBT Working Party on Red Cell 
Immunogenetics and Blood Group Terminology at the 2012 
annual meeting in Cancun (Table 1).10 The related antigens 
LKE and PX2, as well as P, are discussed in the GLOB blood 
group system review also published in this issue.11  
Table 1. The P1PK blood group system





The Pk antigen is also known as the Burkitt lymphoma 
antigen and has been classified as CD77.12 Yet another name, 
Gb3, is often used when the Pk structure is expressed on 
cells other than RBCs. This is in analogy with Gb4 being an 
alternative and more biochemically useful name for P.
Biochemistry
The P1PK and GLOB antigens are related and are 
structurally of a glycan nature. Depending on which 
carbohydrate residues are added to lactosylceramide 
(LacCer), different series of glycosphingolipids are formed. 
Glycosphingolipids were first described by Thudichum in 
1884, and he named them after the inscrutable Egyptian 
Sphinx, as both the structure and the function were unknown 
at the time.13 These molecules consist of a sugar moiety with 
a lipid ceramide tail; they make up the outer leaflet of cell 
membranes together with phospholipids, cholesterol, and 
glycerolipids. Lipids are organised in microdomains such as 
glycosynapses and lipid rafts.14
The P1PK antigens, as well as the GLOB system and 
collection antigens, are formed on the same precursor, LacCer, 
which is the most common precursor for glycosphingolipids 
in mammals and birds.15 Pk (other names include 
globotriaosylceramide, Gb3, ceramide trihexoside, and CTH) 
belongs to the globo-series, and P1 (also known as nLc5) to 
the neolacto/paraglobo-series. 
The biochemistry of the P1 blood group antigen was 
partially elucidated by Morgan and Watkins16 in the 1960s by a 
series of experiments on hydatid cyst fluid from sheep infected 
by the tapeworm Echinococcus granulosus. They purified 
P1-specific components and showed that a glycoprotein 
containing the Galα1-4Galβ1-4GlcNAc trisaccharide reacted 
as a P1 determinant. Some years later, Marcus17 managed to 
extract P1 glycolipids from RBCs. In 1974, the Pk structure 
was identified as CTH by Naiki and Marcus.6
The 4-α-galactosyltransferase (α4Gal-T/P1Pk synthase) 
catalyzes the transfer of galactose to the galactose residue on 
LacCer, producing the Pk antigen. In another pathway, the P1 
antigen is formed by three sequential glycosylation reactions, 
the last one performed by the P1Pk synthase. Furthermore, 
other glycosyltransferases form additional blood group 
antigens associated with the P1PK/GLOB systems and 
collection, such as Forssman (FORS1), globo-H, and globo-A 
(Fig. 2).18–20
It has been debated whether the Pk and P1 antigens exist 
on glycoproteins in the human RBC membrane, but according 
to Yang et al.21 glycolipids are the sole carriers of these antigens 
on RBCs. 
Antigens and Antibodies in the System
Different combinations of the P1, P, and Pk antigens give 
rise to the following phenotypes: P1, P2, P1k, P2k, and p (Table 
2). The prevalence of the P1 phenotype varies among different 
ethnic groups, ranging from 90 percent among Africans to 80 
percent in whites down to 20 percent in Asians.10,23 On RBCs, 
P1 expression changes during fetal development. The antigen 
is found as early as week 12 but weakens during gestation.24 At 
birth the expression is low, and it takes up to 7 years before full 
expression is reached.25 The strength of the antigen expression 
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Fig. 2 The biochemical and genetic relationship between the 
antigens (black boxes) of the P1PK blood group system and other 
related carbohydrate antigens.
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as early as 1953 to be dependent on dosage.26 The discovery 
of a P1/P2-predictive single-nucleotide polymorphism (SNP) 
did indeed prove this proposal to be correct, and it could be 
confirmed with traditional serology, antigen site density 
measurement by flow cytometry, and quantification of 
transcription levels by real-time polymerase chain reaction.27
Table 2. A summary of phenotypes and possible antibodies for the 
P1PK/GLOB blood groups
Phenotype Prevalence Antigens present on RBC Antibodies in serum
P1 20–90% P1, Pk, P —
P2 10–80% Pk, P Anti-P1*
p rare — Anti-PP1Pk
P1k rare P1, Pk Anti-P**
P2k rare Pk Anti-P and P1**
*Not always present, detectable, or both.
**Anti-PX2 can be present.22
Individuals with the In(Lu) phenotype express lower 
amounts of P1 antigen.28 In 2008 Singleton et al.29 found that 
the majority (21 of 24) of such individuals are heterozygous for 
mutations in their EKLF gene. This suggests that expression 
of Pk and P1 on RBCs may depend on binding of the erythroid 
transcription factor EKLF to the A4GALT promoter.
The Pk antigen was first thought to be a low-prevalence 
antigen, but later it was understood that nearly all the antigens 
are masked by addition of β3GalNAc to form globoside, the P 
antigen.30 RBCs from P1 individuals express more Pk antigen 
compared with those from P2 individuals.27,31 The rare null 
phenotype, p, lacks the Pk, P, and P1 antigens (Table 2). 
However, additional phenotypes might exist: Kundu et al.32,33 
described individuals with either a weak P or a weak Pk antigen. 
The frequency of the p phenotype has been estimated at 
5.8 per million in Europeans,34 but for Swedes in Västerbotten 
county in Northern Sweden the number of p individuals 
is significantly higher (141 per million).35 The phenotype 
also seems to be more common in Japan and among Amish 
people.36,37 The frequency of p in the donor population in Israel 
is comparable to that in other populations, but among Jews 
who immigrated to Israel from North Africa the p phenotype 
prevalence is 10 times as high.38
Naturally occurring antibodies of the IgM, IgG, or both 
classes are formed against the missing P1/Pk carbohydrate 
structures (Table 2), in the same way as they are against the 
A/B carbohydrate structures in the ABO blood group system. 
Anti-P1 is usually a weak and cold-reactive antibody 
not implicated in hemolytic transfusion reaction (HTR) 
or hemolytic disease of the fetus and newborn (HDFN). 
However, some antibodies against P1 have been reported to 
react at 37˚C, bind complement, and cause both immediate 
and delayed HTRs.39–41
Anti-PP1Pk can cause HTR, but HDFN has not been 
reported. Instead, some of the women with anti-PP1Pk, or 
with anti-P in the globoside-deficient null phenotypes of the 
GLOB blood group system, suffer from recurrent spontaneous 
abortions.42,43 The fetus as well as the newborn express low 
amounts of the P1, P, and Pk antigens, but the placenta shows 
high expression and is therefore a possible target of the 
antibodies that may be the cause of the miscarriages.43 It has been 
suggested that it is mainly the IgG anti-P component in women 
with the p phenotype that attacks the fetally derived cells in the 
placenta.42,43 In a group of 17 female Swedish p individuals, 11 
had experienced at least one spontaneous abortion.44 
The anti-PP1Pk found in individuals with the p phenotype 
was previously called anti-Tja, named after Mrs. J in whose 
serum this antibody specificity was first found in association 
with a tumor.2
NOR antigen expression, a low-prevalence polyaggluti-
nable state, was first described in 1982 in a patient living in 
Norton, Virginia, hence the name.45 So far, it has only been 
found in two families, one in the United States and one in 
Poland.45,46 The RBCs of the initial patient were agglutinated 
by 75 percent of tested ABO-compatible sera but were not 
agglutinated by any lectin known to react with other types of 
polyagglutinable RBCs. The polyagglutination was inhibited 
by avian P1 substance, and a possible relation to the P1PK 
blood group system was suggested.45 Family studies showed 
that the antigen was inherited and that anti-NOR is present 
in most adult human sera; it has therefore been called a 
polyagglutinin. It is unknown whether this kind of antibody 
is clinically significant, because transfusion of NOR+ blood is 
such a rare event.10
Genetics and Molecular Basis
The P1PK (A4GALT) Gene
The gene encoding the implicated 4-α-galactosyl-
transferase (α4Gal-T, EC 2.4.1.228) was cloned in 2000 by 
three independent research groups47–49 and was originally 
only found to give rise to the Pk antigen. The gene is located 
on the long arm of chromosome 22 and consists of four exons 
with the whole coding region in the last exon (Fig. 3). This 
gene encodes a type II transmembrane glycoprotein with 
353 amino acids and is highly conserved among different 
species.48,50 The protein sequence contains a characteristic 
DXD motif (amino acids 192–194), which is a conserved 
motif existing in nearly all glycosyltransferases.51 It has been 
P1PK blood group system review
28 IMMUNOHEMATOLOGY, Volume 29, Number 1, 2013
proposed that this motif participates in the coordination of the 
metal ion and therefore also in the binding of the nucleotide 
part of the uridine diphosphate donor sugar.51 The crystal 
x-ray structure of the enzyme has not been solved yet, and 
the type of cation A4GALT required for its function has not 
been clarified. The promoter region of the gene has binding 
sequences for the transcription factor AP-1 (TGAGTCA), 160 
bp upstream of the transcription start according to a computer 
search done by Hughes et al.52 In another study, it was shown 
that the promoter contains three binding sites for Sp1, four GC 
boxes, but no TATA or CCAAT boxes.53 However, a specific 
reason why this gene is expressed in erythroid tissues has not 
been reported.
A major enigma has been why the P1 antigen is always 
absent in the p phenotype. Different theories have been 
proposed. One model suggested that the same enzyme, 
α4Gal-T, is able to transfer galactosyl residues to both LacCer 
and paragloboside, but to use the latter as the acceptor, a 
regulatory protein is required.54 Another hypothesis suggested 
that two different enzymes exist, both of which must be 
inactivated to cause the p phenotype.54 This model was 
supposedly supported by a study showing that microsomal 
enzymes from P1 kidneys could synthesize both P1 and Pk, 
whereas enzymes from P2 kidneys could only produce Pk.55 A 
third model proposed a single gene with three alleles, one allele 
coding for a α4Gal-T using LacCer and paragloboside as the 
possible acceptors, one allele using LacCer only, and the third 
allele coding for an inactive form of the transferase.56 However, 
no polymorphisms in the coding region of the A4GALT gene 
appeared to explain the P1/P2 phenotypes. Hence the theory 
with one gene encoding for both P1 and Pk was temporarily 
abandoned.47 Iwamura et al.57 proposed that transcriptional 
regulation, caused by two different polymorphisms in 
the 5 -́regulatory region of A4GALT, might instead be the 
underlying reason for the P1/P2 phenotypes. However, these 
findings could not be verified in their own transcription assay 
or in two other independent studies.58,59
In 2010, it was demonstrated that the A4GALT product 
could also synthesize P1 antigen.60 A genetic marker with 
which prediction of P1 versus P2 phenotype could be achieved 
was reported when a novel A4GALT transcript, containing 
exon 1 and a new exon, designated exon 2a, was discovered.27 
This exon contains a P1- versus P2-associated polymorphism 
(42C/T), which also opens a short potential reading frame in P2 
alleles. However, the mechanism by which this SNP operates is 
still unknown, even if 42T was shown to be correlated to lower 
A4GALT-mRNA levels.27 The authors hypothesize that either 
the new transcript, the hypothetical P2-related peptide, or the 
SNP in the genomic sequence itself may downregulate the 
transcription of A4GALT in P2 individuals. Alternatively, yet 
other polymorphisms closely linked in cis with this SNP could 
be involved. Several candidate SNPs occur in close proximity to 
exon 2a and 42C/T, as do potential binding sites for erythroid 
transcription factors. No matter which mechanism is active, 
typing for the 42C/T polymorphism correctly predicted the P1/
P2 phenotype in 207 of 208 common Swedish blood donors, 
and full concordance was recently obtained also in 200 Asian 
donors (100 P1 and 100 P2).27,61 
To date, 29 mutations in 33 alleles of the A4GALT gene 
have been found to cause the p phenotype.44,62,63 For a complete 
list of these mutations and alleles, see the homepage of the 
International Society of Blood Transfusion (ISBT; www.
isbtweb.org). Two silent polymorphisms, 903G>C (P301P) 
and 987G>A (T329T), as well as one missense mutation, 
109A>G (M37V), with no apparent effect on the α4Gal-T, 
have also been documented.47 These polymorphisms were 
found to be organized into different haplotypes and linked to 
upstream and downstream SNPs.58 In addition, a few other 
noncritical polymorphisms have been found in combination 
with enzyme-crippling, p-associated mutations.
A missense mutation in the A4GALT gene causing an 
amino acid change, Gln211Glu, was found in individuals 
positive for the rare NOR antigen.64 This is believed to make 
the A4GALT-encoded enzyme add a galactose to the P antigen, 
thereby forming NOR. Thus, in addition to making P1 and Pk 
antigen, the Gln211Glu form of α4Gal-T also makes NOR. We 
sequenced the A4GALT genes of NOR+ family members and 
found that the NOR-specific SNP (631C>G) was linked to the 
P1-associated exon 2a SNP 42C.64 Further elongation of the 
NOR antigen (also called NOR1) can give rise to NORint and 
NOR2,65 two glycolipid structures not yet given blood group 
status by the ISBT.







Fig. 3 The genomic organization of the A4GALT gene (not drawn to scale). The numbers in the boxes represent the exon number and 
numbers below the boxes represent the number of base pairs in the exon. The black box shows the open reading frame (ORF).
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Tissue Distribution 
The expression of glycosphingolipids often shows a wide 
histological distribution but varies among tissues and species. 
Expression of the A4GALT-derived Pk and P1 antigens has 
been studied in several species.48,66,67 Studies on mouse tissues 
show expression patterns similar to those found in humans, 
although some differences have been noted.66 
The P1 structure is found as glycolipids, glycoproteins, or 
both in many organisms such as the nematode (Ascaris suum), 
tapeworm (Echinococcus granulosus), earthworm (Lumbricus 
terrestris), liver fluke (Fasciola hepatica), bacterium (Neisseira 
gonorrhoe), and pigeon.68 The Pk antigen is also expressed in 
several strains of bacteria.69 
In humans, glycosphingolipids can be useful as surface 
markers of normal erythrocyte differentiation and of 
erythroleukemias.70 The Pk and P1 antigens are expressed on a 
number of other cells in addition to RBCs, but various studies 
using different antibodies or methods have come to different 
conclusions about where they are expressed. Pk has been 
detected in plasma,41,71 but no such reports about P1 in plasma 
or about Pk and P1 in secretions are available. 
The P1 antigen is expressed on B lymphocytes, 
granulocytes, and monocytes.72 The Pk antigen has been found 
on all leucocytes (except NK cells),72 fibroblasts,30 platelets, 
and smooth muscle cells of the digestive tract and urogenital 
system73 and is a differentiation antigen expressed on a subset 
of tonsillar B cells in the germinal center.74 High expression 
of Pk in the kidney has been implicated in susceptibility to 
hemolytic uremic syndrome (HUS), further discussed in the 
section on disease associations. The mechanism behind the 
high renal expression might be related to enhanced A4GALT 
gene transcription and reduced α-galactosidase gene activity.52 
Recently, it has also been shown that small amounts of Pk 
together with higher amounts of P are present on intestinal 
epithelial cells.75 
Northern blot studies of human organs showed high 
expression of the A4GALT gene in kidney and heart in one 
study,47 while another report described high expression in 
spleen, liver, testis, and placenta, in addition to kidney and 
heart.49 
Disease Associations
The Pk and P1 antigens can act as membrane receptors for 
several pathogens and toxins, summarized in Table 3.
Viruses
Although initial studies implied a facilitating role for Pk in 
human immunodeficiency virus (HIV) infection, recent work 
has suggested that Pk is protective when accumulated owing 
to reduced activity of α-galactosidase A in Fabry disease, an 
X-linked lysosomal storage disorder.84 In addition, a soluble 
analogue of Pk prevents HIV infection in vitro.77,85 Another 
study showed that peripheral blood mononuclear cells (PBMCs) 
with P1k phenotype were highly resistant to infection, whereas 
PBMCs with the p phenotype showed increased susceptibility 
to infection.76 Furthermore, Pk-liposome fusion into the Pk-
deficient Jurkat T-cell line reduced productive X4 HIV-1 
infection, as did overexpression of Pk synthase. Accordingly, 
siRNA silencing of the Pk synthase gene increased the cells’ 
HIV susceptibility.76
Bacteria
Uropathogenic Escherichia coli expressing pap-encoded 
PapG adhesins bind to Pk and P1,78,79 and both the Streptococcus 
suis adhesin and the PA-IL lectin from Pseudomonas 
aeruginosa use Pk (Gb3) and P1 as receptors.79,80,83,86 
Furthermore, Pk is the receptor for Shiga toxin from Shigella 
dysenteriae (Stx) or certain E. coli strains (Stx1 and Stx2) on 
renal epithelium, platelets, and endothelium.81,82 
A disease connected to the Pk antigen is Fabry disease, in 
which deficiency of the lysosomal enzyme α-galactosidase A 
causes accumulation of sphingolipids, mainly Pk, in some cell 
types and body fluids.87 It has been shown that mice with Fabry 
disease are protected against Stx from enterohemorrhagic 
E. coli (EHEC).88 These data are surprising because Pk is the 
cellular receptor for Stx and therefore a higher sensitivity 
would be expected. The authors hypothesize that the excess 
Pk can work as a toxin sink, which allows the toxin to bind 
to Pk in tissues that normally do not have high expression 
Table 3. A selection of pathogens and toxins with a relationship to 




HIV AIDS Pk 76,77
Uropathogenic Escherichia coli UTI Pk, P1 78,79
Streptococcus suis Meningitis Pk, P1 80
Shigella dysenteriae (Shiga toxin) Dysentery Pk 81
Escherichia coli O157 (Stx 1/2) HUS, hemorrhagic 
colitis
Pk 81,82





HIV = human immunodeficiency virus; AIDS = acquired immune deficiency 
syndrome; UTI = urinary tract infection; HUS = hemolytic uremic syndrome.
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and cannot be affected by the toxin. EHEC infection can 
induce HUS, which leads to hemolytic anemia, renal failure, 
and thrombocytopenia.89 According to Furukawa et al.,90 the 
mechanism behind the thrombocytopenia might be that Stx 
binds to Pk in immature megakaryoblasts and induces their 
apoptosis, leading to the restraint of platelet production in 
the bone marrow. The Pk antigen has been shown to mediate 
apoptotic signals after the binding of both Stx and anti-Pk 
(CD77 monoclonal antibody). These ligands trigger two 
completely different apoptotic pathways, one caspase- and 
mitochondria-dependent and one reactive oxygen species–
dependent.91 It has also been shown that patients with HUS 
have lower levels of Pk glycolipid in their sera compared with a 
healthy control group.92 These authors propose that circulating 
Stx could bind to Pk glycolipids in sera during infection, which 
may reduce the amount of Stx binding to the target cells. 
Consequently, patients with low serum levels of Pk would have a 
higher susceptibility to EHEC infections. Another study states 
that only Pk and not P1, as earlier believed, is the receptor for 
Stx, and mice without Pk lose sensitivity to Stx.93 
Cancer
Altered glycosylation patterns of glycosphingolipids 
such as neoexpression, underexpression, or overexpression 
are characteristic of cancer cells.94 One example is the first 
described p individual (lacking Pk, P, and P1 antigens), who had 
a gastric tumor that expressed P1 antigen. Levine95 proposed 
that the antibodies made against the Pk, P, and P1 antigens 
prevented further growth of the tumor. Altered expression 
of Pk antigen has also been described in ovarian carcinomas, 
colon cancer, breast cancer, and B-cell lymphomas.96 It has 
even been suggested that Stx, which specifically binds to Pk, 
could be used as a targeted cancer therapy.96
Summary
The history of the P1PK blood group system is complex 
and not easy to grasp because of several changes of 
nomenclature. In addition, the biochemical background and 
genetic basis have caused long debates, and even today many 
basic questions remain to be solved. However, step by step 
the biochemical and genetic basis underlying the antigens 
expressed in this system has been revealed. The most recent 
but certainly not the final step came when it was clarified that 
the A4GALT gene is responsible not only for Pk expression but 
also for P1 and even NOR expression. As a result, the Pk and 
later the NOR antigen joined the P1 antigen, and the system 
name was changed to P1PK.
Å. Hellberg et al.
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